Introduction {#s1}
============

Triclosan (2,4,4′-trichloro-2′-hydroxy-diphenyl ether, TCS) is a synthetic antibacterial compound largely utilized in personal and household products such as toothpastes, shampoos, cosmetics, antibacterial soaps, deodorants, kitchen utensils, bedding and clothing (Rodricks et al., [@B42]). Given the ubiquity of such products, humans are continually exposed to TCS (Chalew and Halden, [@B10]; Reiss et al., [@B41]) through both skin and oral absorption pathways (Moss et al., [@B30]; Sandborgh-Englund et al., [@B44]). TCS was recently detected in 100% and 51% of urine and cord blood samples, respectively, obtained from 181 expectant mothers in New York (Pycke et al., [@B38]).

TCS exhibits several additional biological activities that are unrelated to its antibacterial action, many of which affect specifically the endocrine system. Reports of the estrogenic activity of TCS are mixed, for example it can amplify estrogen action *in vivo* (Jung et al., [@B20]; Louis et al., [@B26]), or reduces sulfonation of estradiol and estrone (James et al., [@B19]), but acts as an antagonist at the estrogen receptor (ER; Ahn et al., [@B2]). A large body of evidence indicates that the exposure of female rats to TCS reduces the thyroid hormones (Stoker et al., [@B47]). The oral administration of TCS decreases dose-dependently the level of circulating thyroxine (T4) in weanling female rats (Witorsch, [@B56]). The treatment with TCS in pregnant rats decreases total serum triiodothyronine (T3) and T4 (Rodríguez and Sanchez, [@B43]). This decrease in thyroid hormone results in reduced negative feedback on the hypothalamus-pituitary axis enhances thyroid releasing hormone (TRH) secretion, which would in turn promote excess prolactin (PRL) secretion (Tohei et al., [@B50]). PRL elevation was found in 21% of patients with overt hypothyroidism, and 8% of patients with subclinical hypothyroidism (Goel et al., [@B15]). Hyperprolactinemia is a major neuroendocrine-related cause of reproductive disturbances in women.

In females, the estrous cycle and ovarian function are controlled by the hypothalamic-pituitary-gonadal (HPG) axis. The pulse release of gonadotrophin-releasing hormone (GnRH)/luteinizing hormone (LH) and generation of preovulatory surge-like LH release (LH-surge) are altered by the feedback action of estradiol (E2; Adachi et al., [@B1]). Kisspeptin neurons in the arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) have been demonstrated to be responsible for mediating the feedback effects of E2 on GnRH/LH secretion (Kinoshita et al., [@B21]). Approximately 90% of GnRH neurons express the kisspeptin receptor G protein-coupled receptor 54 (GPR54; Pinilla et al., [@B37]). The activation of GPR54 can increase the frequency and amount of the GnRH/LH secretion (Stathatos et al., [@B46]). Growing evidence indicates that, through GnRH, ARC-kisspeptin neurons control tonic pulsatile LH release (Qiu et al., [@B39]; Clarkson et al., [@B11]), and AVPV-kisspeptin neurons regulate the generation of the LH surge to induce ovulation (Ohkura et al., [@B35]). A high proportion of ARC- and AVPV-kisspeptin neurons in female rats also express PRL receptors (Kokay et al., [@B22]). Several lines of evidence suggest that high PRL levels inhibit ARC-kisspeptin expression during lactation (Araujo-Lopes et al., [@B3]). Exogenous PRL administration prevents the occurrence of preovulatory LH surges in intact female rats (Araujo-Lopes et al., [@B3]). Therefore, investigating whether TCS through decreasing thyroid hormones to increase PRL secretion affects the hypothalamic kisspeptin neurons is of great interest to us.

To evaluate influence of TCS on reproductive endocrine and underlying molecular mechanisms, we in the present study examined the estrous cycle and ovarian morphology, hypothalamic kisspeptin expression, hypothalamic-pituitary-reproductive endocrine, activities of hypothalamic-pituitary-thyroid axis and serum PRL concentration in adult female mice treated with TCS (1, 10, or 100 mg/kg) for 50 days. Our results suggest that in adult female mice, TCS exposure (≥10 mg/kg) through reducing thyroid hormones causes hyperprolactinemia that then suppresses hypothalamic kisspeptin synthesis, thereby disrupting the reproductive endocrine and ovarian function.

Materials and Methods {#s2}
=====================

Animals {#s2-1}
-------

This study was carried out in accordance with the recommendations of "experimental animals guidelines established by the Laboratory Animal Research Institute". The protocol was approved by "Ethical Committee of the Nanjing Medical University". Female ICR mice (Oriental Bio Service Inc., Nanjing) at 12 weeks of age (30 ± 2 g) were housed in stainless steel cages with wood bedding to minimize additional exposure to endocrine disrupting chemicals (temperature 23 ± 2°C, humidity 55 ± 5%, 12:12 h light/dark cycle, and lights from 06:00) in Animal Research Center of Nanjing Medical University. They received food and water *ad libitum*. Their body weight was measured every day. All efforts were made to minimize animal suffering. Every early morning (09:00 h), estrous cyclicity was examined using vaginal cytology (Caligioni, [@B8]).

Administration of TCS {#s2-2}
---------------------

TCS (\>99% purity) was purchased from Sigma-Aldrich (Sigma-Aldrich Inc., St. Louis, MO, USA). TCS was dissolved in dimethyl sulfoxide (DMSO), and then diluted with corn oil (final concentration of 0.5% DMSO). After 3--4 regular estrous cycles were determined, the mice were given the oral intake of TCS at doses of 1, 10 and 100 mg/kg per day at 08:00 h. A recent study (Wang et al., [@B54]) reported that the urinary TCS level in gestational mice receiving 10 mg/kg TCS is equivalent to high urinary TCS levels of spontaneous abortion patients. Thus, these doses resemble the exposure level to TCS in spontaneous abortion patients. Control mice were treated with oral intake of 0.5% DMSO.

Measurement of TCS {#s2-3}
------------------

To measure urinary TCS levels, each mouse was housed in a metabolic cage for 5 days. The urine samples (0.2--0.3 ml/mouse) within 12 h after the administration of TCS were collected and stored at −80°C until measurement. The TCS concentrations of urinary (1 ml/mouse) were measured using an established method (Wang et al., [@B52]). Briefly, the urine samples hydrolyzed with β-glucuronides (Type H-1 from Helix Pomatia, Sigma-Aldrich, St. Louis, MO, USA) were concentrated by a solid phase extraction (SPE; 500 mg/3 mL; Supelco, ENVI-18) and analyzed using liquid chromatography electrospray ionization tandem mass spectrometry (HPLC-MS/MS, Agilent 1290-6490, Agilent Technologies, Santa Clara, CA, USA). Analysts were blinded to all information concerning subjects during the tests.

Histological Examination of Ovarian {#s2-4}
-----------------------------------

The mice at diestrus were anesthetized with intraperitoneal (i.p.) injection chloral hydrate (400 mg/kg). Both ovaries were dissected and fixed in Bouin's fluid. The samples were dehydrated through a graded series of alcohol, cleared in xylene, and then embedded in paraffin wax. After the sections (5 μm) were deparaffined and rehydrated, the sections were stained with hematoxylin and eosin (HE). The classification of follicular stages was made following the morphological criteria as described previously (Myers et al., [@B32]). Follicles were counted using a conventional light microscope (Olympus DP70, Japan) with a 40× objective. Antral follicles (early antral, antral and preovulatory follicles) and corpora lutea were counted in every 6th section (30 μm apart). Then, the numbers of antral follicles and corpora lutea were multiplied by 6 to give a total number in each ovary.

Immunohistochemistry of Kisspeptin Neurons {#s2-5}
------------------------------------------

Mice were anesthetized with chloral hydrate (400 mg/kg, i.p.) and perfused transcardially with 4% paraformaldehyde. Brains were transferred gradually into 15% and 30% sucrose until they settled. Sections (40 μm thick) through the AVPV (Bregma +0.50 to +0.02 mm) the ARC area (Bregma −1.46 to −1.70 mm; Marraudino et al., [@B27]) were cut using a cryostat. Free-floating sections were incubated in 0.5% sodium metaperiodate for 20 min and then in 1% sodium borohydride for 20 min. The sections were pre-incubated with 1% normal fetal goat serum for 60 min, and then incubated in rabbit anti-kisspeptin polyclonal antibody (1:1000, Catalog\# AB9754, Millipore, Billerica, MA, USA) at 4°C for 24 h. Then, the sections were treated with biotin-conjugated goat anti-rabbit IgG (1:400; vector laboratories, Burlingame, CA, USA) at 37°C for 2 h. The immune-reactivity was visualized with the standard avidin-biotin complex reaction with Ni-3, 3-diaminobenzidine (DAB, Vector Laboratories). In every experiment, incubation of sections without the primary antibody served as negative controls for immunohisto-chemistry. Kisspeptin-positive (kisspeptin^+^) cells in AVPV (AVPV-kisspeptin^+^ cells) and ARC (ARC-kisspeptin^+^ cells) were observed by conventional light microscope (Olympus DP70; Olympus, Tokyo, Japan) with a 40× objective.

Measurement of Serum Hormones {#s2-6}
-----------------------------

Orbital blood (\~300 μl) was obtained under anesthetized conditions with chloral hydrate (400 mg/kg, i.p.) at 1600--1700 h. Serum (\~100 μl) was separated by centrifugation at 4°C and stored at −80°C until assay. The levels of serum estradiol (E2), progesterone (P4), LH and follicle-stimulating hormone (FSH) were measured on the day of diestrus (*group I*). The measurement of T3, T4, thyroid stimulating hormone (TSH), thyrotropin-releasing hormone (TRH) and PRL had no limit for any estrous cyclicity (*group II*). The serum sample (5 μl) was needed for each assay (E2, P4, LH, FSH, PRL, T3, T4, TSH or TRH) using commercial enzyme-linked immunosorbent assay (ELISA) kits (Uscn Life Science Inc., Houston, TX, USA). The measurement of each sample was repeated 2 times to obtain an average value. The sensitivities were 47.1 pg/ml for T3, 1.4 ng/ml for T4, 19.3 pg/ml for TSH, 0.18 μIU/ml for TRH, 2.0 pg/ml for E2, 0.2 ng/ml for P4, 0.2 ng/ml for LH, 0.4 ng/ml for FSH and 0.4 ng/ml for PRL, respectively. The intra- and inter-assay coefficients of variation were 4.5% and 7.2% for T3, 4.3% and 7.5% for T4, 3.2% and 9.5% for TSH, 5.6% and 7.2% for TRH, 6.0% and 5.8% for E2, 5.8% and 8.4% for P4, 5.5% and 8.9% for LH, 4.3% and 10.3% for FSH, 4.7% and 4.9% for PRL. For determination of the LH surge, the repetitive blood sampling was undertaken at 1600, 1700 and 1800 h, respectively, on the day of proestrus (*group III*). The mice were anesthetized with ketamine (80 mg/kg) and xylazine (4 mg/kg) and a needle was inserted into a caudal vein at 1400 h. The mice were gently restrained in a cardboard tube, and the blood sample (\~50 μl per time) was collected without anesthesia using heparinized syringes. After each blood collection, an equivalent volume of heparinized saline (5 U/ml normal saline; CP Pharmaceuticals Ltd, Wrexham, UK) was injected. Serum (\~15 μl) was stored at −80°C for subsequent ELISA of LH.

Reverse Transcription, Quantitative Polymerase Chain Reaction (RT-qPCR) {#s2-7}
-----------------------------------------------------------------------

The POA area (0.76 mm anterior to Bregma and 0.50 mm posterior to Bregma; Mayer and Boehm, [@B28]), the AVPV area (0.50 mm anterior to Bregma and 0.02 mm posterior to Bregma) at proestrus and the ARC area (−1.46 mm anterior to Bregma and −1.70 mm posterior to Bregma; Marraudino et al., [@B27]) at diestrus were collected from the frozen slices (200 μm thick) of brain using 16-gauge stainless steel tubing, and then stored at −80°C until assay. Total RNA of POA, AVPV or ARC regions was isolated using Trizol reagent (Invitrogen, Camarillo, CA). RNA (1 μg) was reverse-transcribed into cDNA using a Prime-Script RT reagent kit (Takara) for quantitative PCR (ABI Step One Plus) in the presence of a fluorescent dye (SYBR Green I; Takara). The synthesized cDNA was stored at −20°C until qRT-PCR was performed. The following primers were used for real-time PCR as described previously (Xi et al., [@B58]): *GnRH* F-GGGAAAGAGAAACACTGAACAC, R-GGACAGTACATTCGAAGTGCT;*kiss1* F-GAATGATCTCAATGGCTTCTTGG, R-TTTCCCAGGCATTAACGAGTT; *GAPDH* F-ACCACAGTCCATGCCATCAC, R-TCCACCACCCTGTTGCTGTA. All samples were run in triplicate for each gene and for GAPDH (as housekeeping gene). There was no difference in GAPDH expression among the groups. The relative expression of genes was determined using the 2^−∆∆ct^ method with normalization to *GAPDH* expression. On the basis of melting curve analyses, there were no primer dimers or secondary products formed.

Administration of Drugs {#s2-8}
-----------------------

Levothyroxine (L-T4; Sigma-Aldrich Inc., St. Louis, MO, USA) dissolved in 0.9% saline was subcutaneously (s.c.) injected at dose of 20 μg/kg/day (Cao et al., [@B9]). Quinpirole (Quin; Sigma-Aldrich Inc., St. Louis, MO, USA) was dissolved in 0.9% saline and injected (i.p.) at dose of 2 mg/kg (Zhang et al., [@B60]).

Kisspeptin-10 \[Kp-10, KiSS-1 (112--121)/metastin (45--54; human)\] (Sigma-Aldrich Corp) was dissolved in DMSO, and then was diluted by 0.9% saline to a final concentration of 0.5% DMSO. For repeated intracerebroventricular (i.c.v.) injection of kisspeptin-10, the mice were anesthetized with chloral hydrate (400 mg/kg, i.p.) and then placed into a stereotaxic instrument (Stoelting, Wood Dale, IL, USA). A small hole (2 mm diameter) was drilled in the skull using a dental drill. A guide cannula (26-gauge, Plastics One, Roanoke, VA, USA) was implanted into the right lateral ventricle (0.3 mm posterior, 1.0 mm lateral and 2.5 mm ventral to Bregma) and anchored to the skull with three stainless steel screws and dental cement. On day 3 after surgery, the dummy cannula was removed from the guide cannula, and replaced by infusion cannulas (30 gauge) connected by polyethylene tubing (PE10; Becton Dickinson, Sparks, MD, USA) with a stepper-motorized micro-syringe (Stoelting, Wood Dale, IL, USA). The kisspeptin-10 (1 nmol/3 μl; Gottsch et al., [@B16]) was injected daily for successive 7 days. The injection of kisspeptin-10 was given at 30 min after TCS administration. This dose was selected on the basis of the previous report that kisspeptin-10 potently elicits the LH secretion (Navarro et al., [@B34]). The mice treated with injection (i.c.v.) of vehicle (0.9% saline) were served as the control group.

Mice were ovariectomized (OVX) under the anesthetized conditions with intramuscular injections of ketamine (80 mg/kg) and xylazine (4 mg/kg) at day 43 of TCS exposure. After surgery, the OVX mice received a subcutaneous implant of a silastic tubing (1.57 mm inside diameter; 3.18 mm outside diameter; 10 mm in length; Dow Corning, Midland, MI, USA) that was filled with 20 μg/ml of E2 in olive oil. The E2-treatment for 5 days produced a physiological level of serum E2 (20.71 ± 6.25 pg/ml) in adult female mice. On day 6 after implanting silastic tubing, the mice were given the injection (s.c.) of E2 at doses of 100 μg/kg for two consecutive days to produce a preovulatory high level of E2 (314.38 ± 66.91 pg/ml) that could exert a positive feedback action in AVPV-kisspeptin neurons (Wang et al., [@B53]). The silastic tubing filled with vehicle was implanted in OVX mice as the control group.

Data Analysis/Statistics {#s2-9}
------------------------

All group data in the Figures [1](#F1){ref-type="fig"}--[](#F2){ref-type="fig"}[](#F3){ref-type="fig"}[](#F4){ref-type="fig"}[5](#F5){ref-type="fig"} are expressed as the mean ± standard error of the mean (SEM); all group data in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} are expressed as the mean ± standard deviation (SD). All statistical analyses were performed using SPSS software, version 16.0 (SPSS Inc., Chicago, IL, USA). When analyzing one-variable experiments with more than two groups, differences among means were analyzed using one-factor analysis of variance (ANOVA) followed by Bonferroni *post hoc* tests. Differences at *P* \< 0.05 were considered statistically significant.

![Time chart of experimental procedure. Hollow arrow indicates experimental time (day). "+" indicates the time of drugs administration and examination.](fnmol-11-00006-g0001){#F1}

![Triclosan (TCS) causes prolongation of diestrus. **(A)** Body weights (g) of mice. **(B)** Representative estrous cycles before and after TCS-exposure for 50 days. Connected dots indicate the time of diestrus (D), proestrus (P) or estrus (E), respectively. \*: persistent diestrus; ↑: loss of proestrus. **(C)** Bar graph shows the mean time (day) of one estrous cycle within TCS-exposure. \*\**P* \< 0.01 vs. control mice (one-way ANOVA). **(D)** Bars represent the mean length (day) of diestrus (D), proestrus (P), or estrus (E), respectively, per estrous cycle. \*\**P* \< 0.01 vs. control mice (one-way ANOVA).](fnmol-11-00006-g0002){#F2}

![TCS affects follicle development and ovulation. **(A)** Representative images of ovaries stained with hematoxylin and eosin (HE) in control mice and TCS mice. \#: antral follicles; ↑: atretic follicles; \*: corpora luteum. Scale bars = 200 μm. **(A-i,A-ii)** Bar graphs represent the mean number of antral follicles and corpora luteum at diestrus, respectively. \**P* \< 0.05 vs. control mice (one-way ANOVA).](fnmol-11-00006-g0003){#F3}

![TCS suppresses luteinizing hormone (LH)-surge and kisspeptin expression. **(A)** Each point represents mean levels of LH that are normalized by the LH level at 1600. \*\**P* \< 0.01 vs. control mice (one-way ANOVA). **(B)** Representative picture of kisspeptin immune-staining in anteroventral periventricularnucleus (AVPV) of proestrus control mice and TCS mice. Black arrows indicate AVPV-kisspeptin+ cells. Scale bars = 100 μm. **(C,D)** Bar graphs indicate the levels of AVPV-*kiss1* mRNA in proestrus mice or E2-treated OVX mice. \**P* \< 0.05 and \*\**P* \< 0.01 vs. control mice; ^\#\#^*P* \< 0.01 vs. OVX 10-TCS mice; ^\$\$^*P* \< 0.01 vs. E2-treated ovariectomized (OVX) control mice (two-way ANOVA). **(E)** Representative picture of kisspeptin immune-staining in arcuate nucleus (ARC) of diestrus control mice and TCS mice. Scale bars = 100 μm. **(F)** Bars indicate the levels of ARC-*kiss1* mRNA in diestrus control mice and TCS mice. \**P* \< 0.05 vs. control mice (one-way ANOVA).](fnmol-11-00006-g0004){#F4}

![TCS-reduced kisspeptin causes persistent diestrus and ovary dysfunction. **(A,B)** Bar graphs indicate the levels of AVPV-*kiss1* mRNA and ARC-*kiss1* mRNA in 10-TCS mice treated with Levothyroxine (L-T4) or quinpirole (Quin). \**P* \< 0.05 vs. control mice; ^\#^*P* \< 0.05 vs. 10-TCS mice (two-way ANOVA). Bar graphs represent the length (day) of diestrus **(C)**, the number of antral follicles **(D)** and corpora luteum at diestrus **(E)** in 10-TCS mice treated with L-T4 or Quin. \**P* \< 0.05 vs. control mice; ^\#^*P* \< 0.05 vs. 10-TCS mice; \*\**P*\< 0.01 vs. control mice; ^\#\#^*P* \< 0.01 vs. 10-TCS mice (two-way ANOVA).](fnmol-11-00006-g0005){#F5}

###### 

Prolactin (PRL) and hypothalamic-pituitary-gonad and -thyroid hormones.

                 Control         1-TCS           10-TCS            100-TCS
  -------------- --------------- --------------- ----------------- -------------------
  FSH (IU/L)     1.80 ± 0.42     1.79 ± 0.60     1.46 ± 0.25\*     1.25 ± 0.49\*
  LH (IU/L)      1.08 ± 0.31     0.94 ± 0.38     0.80 ± 0.17\*     0.71 ± 0.26\*\*
  E2 (pg/ml)     20.01 ± 3.88    17.29 ± 2.19    16.57 ± 4.40      15.74 ± 5.15
  P4 (ng/ml)     4.27 ± 0.86     3.87 ± 0.66     3.52 ± 0.45\*     3.18 ± 0.89\*
  PRL (ng/L)     54.95 ± 9.46    55.83 ± 7.25    61.34 ± 8.76\*    62.04 ± 10.00\*
  *GnRH m*RNA    1.00 ± 0.13     0.95 ± 0.18     0.71 ± 0.21\*\*   0.65 ± 0.19\*\*
  T4 (ng/ml)     54.63 ± 13.64   53.74 ± 12.72   44.65 ± 11.79\*   26.19 ± 20.65\*\*
  T3 (ng/ml)     1.67 ± 0.35     1.62 ± 0.30     1.40 ± 0.36\*     1.23 ± 0.55\*\*
  TSH (μIU/ml)   1.26 ± 0.23     1.21 ± 0.28     1.48 ± 0.43\*     1.49 ± 0.35\*
  TRH (ng/L)     0.98 ± 0.30     1.05 ± 0.39     1.29 ± 0.47\*     1.33 ± 0.50\*

*\*P \< 0.05, \*\*P \< 0.01 vs. control*.

###### 

Hypothalamic-pituitary trophic hormones and PRL.

                 Control        10-TCS            10-TCS/L-T4        10-TCS/Quin          10-TCS/Kp-10
  -------------- -------------- ----------------- ------------------ -------------------- -----------------
  FSH (IU/L)     1.80 ± 0.42    1.46 ± 0.25\*     1.69 ± 0.21^\#^    1.73 ± 0.29^\#^      1.68 ± 0.19^\#^
  LH (IU/L)      1.08 ± 0.31    0.80 ± 0.17\*     0.95 ± 0.13^\#^    1.05 ± 0.19^\#\#^    0.96 ± 0.16^\#^
  *GnRH m*RNA    1.00 ± 0.13    0.71 ± 0.21\*\*   0.87 ± 0.05^\#^    0.95 ± 0.06^\#\#^    0.90 ± 0.06^\#^
  PRL (ng/L)     54.95 ± 9.46   61.34 ± 8.76\*    56.47 ± 6.03^\#^   54.55 ± 6.37^\#\#^   59.25 ± 12.17
  TSH (μIU/ml)   1.26 ± 0.23    1.48 ± 0.43\*     1.26 ± 0.21^\#^    1.40 ± 0.52          1.37 ± 0.39
  TRH (ng/L)     0.98 ± 0.30    1.29 ± 0.47\*     1.02 ± 0.23^\#^    1.25 ± 0.29          1.30 ± 0.41

*\*P \< 0.05, \*\*P \< 0.01 vs. control; ^\#^P \< 0.05, ^\#\#^P \< 0.01 vs. 10-TCS mice. L-T4, Levothyroxine; Quin, quinpirole; Kp-10, kisspeptin-10*.

Results {#s3}
=======

Exposure of Female Mice to TCS Prolongs Diestrus {#s3-1}
------------------------------------------------

Female mice (12 weeks old) were treated with the oral gavage of TCS at 1, 10 and 100 mg/kg/day for 50 days, hereafter referred to as 1-TCS, 10-TCS, or 100-TCS mice (Figure [1](#F1){ref-type="fig"}). In comparison with controls (0.95 ± 0.28 ng/ml), the urinary TCS levels were increased by approximately 4-fold in 1-TCS mice (3.82 ± 1.59 ng/ml), 20-fold in 10-TCS mice (21.09 ± 5.78 ng/ml) and 40-fold in 100-TCS mice (40.82 ± 4.48 ng/ml), respectively. One-way repeated measures ANOVA revealed that TCS exposure did not affect body weight (*F*~(3,76)~ = 1.129, *P* \> 0.05; Figure [2A](#F2){ref-type="fig"}): mean body weights in 1-TCS mice (37.40 ± 2.67 g), 10-TCS mice (37.69 ± 2.78 g) and 100-TCS mice (36.60 ± 2.49 g) were not significantly different than control mice (37.81 ± 2.24).

The estrous cycle was monitored using the vaginal smear test. As shown in Figure [2B](#F2){ref-type="fig"}, mice with regular 4--5 day cycles consisting of 1 day in proestrus followed by 1 day in estrus and 2--3 days in diestrus (including 1 day of metestrus) were called "regular cyclers". Estrous cycle length (*F*~(3,76)~ = 18.31, *P* \< 0.01; Figure [2C](#F2){ref-type="fig"}), and specifically diestrus length (*F*~(3,76)~ = 24.17, *P* \< 0.01; Figure [2D](#F2){ref-type="fig"}) was altered by the TCS exposure. Approximately 65% of 10-TCS mice (*P* \< 0.01) and 90% of 100-TCS mice (*P* \< 0.01) had a persistent diestrus (lasting more than 5 days) starting from the 2nd week of TCS exposure.

TCS Exposure Reduces Follicular Development and Ovulation {#s3-2}
---------------------------------------------------------

Ovary weights of 1-TCS mice (7.48 ± 1.55 mg), 10-TCS mice (7.69 ± 2.18 mg) and 100-TCS-mice (7.92 ± 1.44 mg) were not significantly different than control mice (8.12 ± 1.40 mg, *P* \> 0.05, *n* = 20). To examine the possible influence of TCS on follicle development and ovulation, we counted the number of antral follicles and corpora lutea at diestrus using morphological criteria. As shown in Figure [3A](#F3){ref-type="fig"}, ovaries from control mice appeared typical for the diestrus stage. Numerous corpora lutea were observed in these ovaries, some showing clear evidence of recent ovulation. The numbers of antral follicles (*F*~(3,36)~ = 5.675, *P* \< 0.05; Figure [3A-i](#F3){ref-type="fig"}) and corpora lutea (*F*~(3,36)~ = 3.371, *P* \< 0.05; Figure [3A-ii](#F3){ref-type="fig"}) were affected by the TCS exposure, where the 10-TCS mice and 100-TCS mice showed a significant reduction in the number of antral follicles (*P* \< 0.05) and corpora lutea (*P* \< 0.05).

TCS Exposure Causes Decline of HPG Axis {#s3-3}
---------------------------------------

To explore the underlying mechanisms of TCS-caused persistent diestrus and ovary dysfunction, we measured the levels of reproductive hormones (Figure [1](#F1){ref-type="fig"}). At diestrus, the levels of serum FSH (*F*~(3,36)~ = 3.349, *P* \< 0.05; Table [1](#T1){ref-type="table"}), LH (*F*~(3,36)~ = 2.889, *P* \< 0.05), P4 (*F*~(3,36)~ = 4.035, *P* \< 0.05) and PRL (*F*~(3,76)~ = 3.376, *P* \< 0.05) and *GnRH* mRNA (*F*~(3,36)~ = 9.422, *P* \< 0.01), were all affected by TCS exposure. Specifically, 10-TCS mice and 100-TCS mice showed a modest but significant decrease in the levels of LH (*P* \< 0.05 and *P* \< 0.01), FSH (*P* \< 0.05), P4 (*P* \< 0.05) and *GnRH* mRNA (*P* \< 0.01) compared to controls, which were associated with an obvious increase in the level of PRL (*P* \< 0.05). Although the TCS exposure had a tendency to decrease the serum E2 level, this difference did not reach statistical significance (*F*~(3,36)~ = 2.083, *P* \> 0.05). A surge-like LH release (LH surge) was observed between 1600 and 1700 in proestrus control mice and 1-TCS mice, but not in 10-TCS mice and 100-TCS mice (Figure [4A](#F4){ref-type="fig"}).

TCS Exposure Suppresses Hypothalamic Kisspeptin Expression {#s3-4}
----------------------------------------------------------

To further investigate the targets of TCS-reduced HPG axis and LH surge production, we examined kisspeptin expression in AVPV of proestrus mice and ARC of diestrus mice. In proestrus control mice, the kisspeptin+ cells in AVPV (AVPV-kisspeptin+) were located along the third ventricle (Figure [4B](#F4){ref-type="fig"}). In comparison with control mice, the immunoreactivity of AVPV-kisspeptin+ cells in 10-TCS mice and 100-TCS mice was significantly reduced. In diestrus control mice, a large number of kisspeptin+ cells were observed in ARC (ARC-kisspeptin+ cells, Figure [4E](#F4){ref-type="fig"}). The immunoreactivity of ARC-kisspeptin+ cells in diestrus 10-TCS mice and 100-TCS mice was lower than that in control mice. In addition, either the level of AVPV-*kiss1* mRNA at proestrus (*F*~(3,36)~ = 11.512, *P* \< 0.01; Figure [4C](#F4){ref-type="fig"}) or the level of ARC-*kiss1* mRNA at diestrus (*F*~(3,36)~ = 3.614, *P* \< 0.05; Figure [4F](#F4){ref-type="fig"}) in 10-TCS mice and 100-TCS mice were significantly reduced. To avoid the influence of gonadal hormones and estrous cycles in kisspeptin expression, mice were OVX mice and then treated with E2 (100 μg/kg) to produce a preovulatory high level of E2 (Murphy, [@B31]). As shown in Figure [4D](#F4){ref-type="fig"}, the administration of E2 in control mice exerted a positive feedback regulation in the AVPV-kisspeptin expression (*P* \< 0.01, *n* = 10). In comparison with OVX control mice, the level of AVPV-*kiss1* mRNA in OVX 10-TCS mice was reduced by approximately 40% (*P* \< 0.01, *n* = 10). Although the high dose of E2 could elevate the level of AVPV-*kiss1* mRNA in OVX 10-TCS mice (*P* \< 0.01, *n* = 10), their level of AVPV-*kiss1* mRNA still was less than half of E2-treated control mice (*P* \< 0.01, *n* = 10).

TCS-reduced Thyroid Hormones Leads to Hyperprolactinemia {#s3-5}
--------------------------------------------------------

To further explore the underlying mechanisms of TCS-enhanced secretion of PRL, we measured serum total thyroid hormones (T3 and T4), TSH and TRH (Figure [1](#F1){ref-type="fig"}). As shown in Table [1](#T1){ref-type="table"}; the levels of T3 (*F*~(3,76)~ = 5.170, *P* \< 0.01) and T4 (*F*~(3,76)~ = 15.267, *P* \< 0.01), TSH (*F*~(3,76)~ = 3.919, *P* \< 0.05) and TRH (*F*~(3,76)~ = 3.882, *P* \< 0.05) were each affected by TCS exposure. While T3 and T4 were substantially reduced in 10-TCS (*P* \< 0.05) and 100-TCS (*P* \< 0.01) mice, TSH (*P* \< 0.05) and TRH (*P* \< 0.05) were increased. Interestingly, the administration of L-T4 at the dose of 20 μg/kg for 20 days starting from day 30 of 10-TCS exposure (Figure [1](#F1){ref-type="fig"}) reduced the previously observed increases in the levels of TSH (*P* \< 0.05, *n* = 10; Table [2](#T2){ref-type="table"}), TRH (*P* \< 0.05, *n* = 10) and PRL (*P* \< 0.05, *n* = 10).

TCS-induced Hyperprolactinemia Suppresses Kisspeptin-Reproductive Endocrine {#s3-6}
---------------------------------------------------------------------------

Thyroid hormone replacement in TCS mice corrected their hyperprolactinemia, next experiments were designed to examine whether the hyperprolactinemia causes the suppression of kisspeptin expression and hypothalamic-pituitary-reproductive endocrine. The results showed that the treatment of 10-TCS mice with L-T4 for 20 days was able to correct the decrease in the level of AVPV-*kiss1* mRNA at proestrus (*P* \< 0.05, *n* = 10; Figure [5A](#F5){ref-type="fig"}) or ARC-*kiss1* mRNA at diestrus (*P* \< 0.05, *n* = 10; Figure [5B](#F5){ref-type="fig"}), which was accompanied by a recovery of *GnRH* mRNA (*P* \< 0.05, *n* = 10; Table [2](#T2){ref-type="table"}), serum LH (*P* \< 0.05, *n* = 10) and FSH (*P* \< 0.05, *n* = 10).

Until now, there have been no commercially available the PRL receptor antagonists (Lan et al., [@B23]). To further determine the involvement of TCS-induced hyperprolactinemia in the down-regulation of kisspeptin-reproductive endocrine, we used a type-2 dopamine receptors agonist quinpirole (Quin), because a recent study (Nakano et al., [@B33]) has reported that TRH-induced PRL release is inhibited by the activation of type-2 dopamine receptors. As expected, the administration of quinpirole (2 mg/kg) for 20 days in 10-TCS mice could prevent the increase in the level of serum PRL (*P* \< 0.05, *n* = 10; Table [2](#T2){ref-type="table"}), but it had no effects on the elevation of TSH (*P* \> 0.05, *n* = 10) and TRH (*P* \> 0.05, *n* = 10). Similarly, the administration of quinpirole for 20 days in 10-TCS mice restored the levels of AVPV-*kiss1* mRNA (*P* \< 0.05, *n* = 10), ARC-*kiss1* mRNA (*P* \< 0.05, *n* = 10) and *GnRH* mRNA (*P* \< 0.01, *n* = 10), as well as serum LH (*P* \< 0.01, *n* = 10; Table [2](#T2){ref-type="table"}) and FSH (*P* \< 0.05, *n* = 10).

To demonstrate that TCS-induced hyperprolactinemia through reducing kisspeptin expression suppresses the reproductive endocrine, the 10-TCS mice were given the injection (i.c.v.) of the GPR45 agonist kisspeptin-10 (Kp-10) for 7 days (Figure [1](#F1){ref-type="fig"}). The results showed that the application of kisspeptin-10 was able to correct the decline of *GnRH* mRNA (*P* \< 0.05, *n* = 10; Table [2](#T2){ref-type="table"}), LH (*P* \< 0.05, *n* = 10) and FSH (*P* \< 0.05, *n* = 10) without altering the increased levels of TSH (*P* \> 0.05, *n* = 10) and TRH (*P* \> 0.05, *n* = 10), or PRL (*P* \> 0.05, *n* = 10).

TCS-suppressed Kisspeptin Impairs Estrous Cycle and Ovary Function {#s3-7}
------------------------------------------------------------------

To confirm whether the TCS-suppressed kisspeptin neurons caused persistent diestrus and ovary dysfunction, 10-TCS mice were treated with L-T4 or quinpirole for 20 days after examined persistent diestrus (Figure [1](#F1){ref-type="fig"}). The results showed that treatment with L-T4 or quinpirole could return the diestrus lengths to normal (*P* \< 0.05 and *P* \< 0.01, *n* = 10; Figure [5C](#F5){ref-type="fig"}) and recover the numbers of antral follicles (*P* \< 0.05, *n* = 10; Figure [5D](#F5){ref-type="fig"}) and corpora lutea (*P* \< 0.05, *n* = 10; Figure [5E](#F5){ref-type="fig"}).

Discussion {#s4}
==========

The results in the present study provides *in vivo* evidence that the exposure of adult female mice to TCS (≥10 mg/kg) reduces thyroid hormones, causing hyperprolactinemia which then suppresses hypothalamic kisspeptin neurons, ultimately disrupting reproductive endocrine and function.

Consistent with the TCS-reduced thyroid hormones in pregnant mice (Cao et al., [@B9]), exposing adult female mice to 10 and 100 mg/kg TCS caused the decline of T4 and T3. Wu et al. ([@B57]) reported that exposure to TCS for such a short time (1 h) concentration-dependently decreases the sodium/iodide symporter (NIS)-mediated iodide uptake, which gave an inhibition constant (Ki) of 21.3 μM. TCS also inhibits thyroid peroxidase (TPO) activity (Wu et al., [@B57]). TPO catalyzes the oxidation of iodide and the addition of iodide to the tyrosine residues of thyroglobulin, making it critical to the synthesis of thyroid hormones (Taurog et al., [@B49]). In addition, TCS likely induces hypothyroxinemia in part through upregulation of hepatic catabolism, drastically increasing pentoxyresorufin O-dealkylase (PROD) activity (Paul et al., [@B36]). It has been reported that patients with hypothyroidism often show hyperprolactinemia (Watanobe and Sasaki, [@B55]). Reduced thyroid hormones in rats can lead to a significant increase in PRL level (Hapon et al., [@B17]). The decline of thyroid hormone probably enhances TRH secretion *via* reduced negative feedback of the hypothalamus-pituitary axis, which promotes the release of both TSH and PRL. The present data suggest that TCS-induced hypothyroidism presents the same scenario, as the elevated levels of serum PRL, TSH and TRH in 10-TCS mice were corrected by L-T4 administration. Hypothyroidism can also induce elevation in vasoactive intestinal peptide, which is capable of increasing PRL secretion (Tohei et al., [@B50]). On the other hand, PRL can regulate its own release by acting on the hypothalamic dopaminergic systems *via* a "short loop feedback", which is mostly responsible for the maintenance of PRL homeostasis. Dopamine has been clearly established as the primary inhibitor of PRL release (Ben-Jonathan and Hnasko, [@B4]). The activation of type-2 dopamine receptors inhibits PRL release (Nakano et al., [@B33]) through rapidly increasing intracellular potassium efflux and reducing calcium influx (Lledo et al., [@B25]). The acute decline of serum PRL levels was observed in OVX rats treated with competitive dopamine transporter inhibitors (Demaria et al., [@B12]). Although we in this study did not examine the hypothalamic dopaminergic systems, we observed that the activation of type-2 dopamine receptors by quinpirole could reduce the level of circulating PRL in TCS mice without the changes in the levels of TRL and TSH. While Szawka et al. ([@B48]) reported that injection (i.c.v.) of kisspeptin-10 to females elicits PRL release. However, in TCS mice the administration of kisspeptin-10 failed to alter the levels of PRL, TSH and TRH.

In female rats, a high proportion of ARC- and AVPV-kisspeptin neurons express the PRL receptors (Kokay et al., [@B22]). In OVX rats, the administration of PRL decreases the ARC- and AVPV-kisspeptin expression, and level of plasma LH (Araujo-Lopes et al., [@B3]). Acute administration of PRL for 1 h can also reduce the level of AVPV-*kiss1* mRNA (Higo et al., [@B18]). In TCS mice, the reduced ARC- or AVPV-kisspeptin expression was recovered by L-T4 or quinpirole that corrected the increase of PRL. Phosphorylation of signal transducer and activator of transcription 5 (STAT5) is known to be a reliable marker of PRL-responsive neurons (Brown et al., [@B6]). Exogenous PRL enhances phosphorylated STAT5 in kisspeptin neurons, while reduction of endogenous PRL inhibits STAT5 phosphorylation (Brown et al., [@B6]). PRL receptor and E2 receptor α (ERα) share a similar expression pattern in the ARC- and AVPV-kisspeptin neurons (Brown et al., [@B5]). The activation of ERα decreases the PRL-induced STAT5 transcriptional activity (Faulds et al., [@B14]). In TCS mice, the enhancing effect of E2 on the AVPV-kisspeptin expression was suppressed, which could be rescued by the quinpirole-corrected increase of PRL. Thus, it is proposed that the activation of PRL receptor suppresses E2-increased AVPV-kisspeptin expression. However, the administration of E2 in adult female mice negatively regulates the ARC-kisspeptin expression (Dungan et al., [@B13]). Moreover, the quinpirole-corrected increase of PRL could prevent the decline of ARC-kisspeptin expression in TCS mice. Thus, the suppression of kisspeptin synthesis by hyperprolactinemia is unlikely to act on ER-mediated signaling. The molecular mechanisms underlying the PRL-inhibited ARC- and AVPV-kisspeptin expression in TCS mice remains to be determined.

ARC- and AVPV-kisspeptin neurons exert critical afferent regulation in the activity of GnRH neurons (Pinilla et al., [@B37]). An abundance of evidence indicates that AVPV-kisspeptin neurons regulate the generation of GnRH and LH surge, and ARC-kisspeptin neurons are involved in the rhythm of GnRH pulse (Ohkura et al., [@B35]). Previous studies have identified that reduced ARC-*kiss1* mRNA and ARC-kisspeptin protein in lactating rats are associated with the suppression of pulsatile GnRH secretion (True et al., [@B51]); the administration of PRL prevents the occurrence of preovulatory LH surges in ovary-intact rats (Araujo-Lopes et al., [@B3]). We found no evidence of an LH surge in TCS mice unless they were also treated with L-T4 (data not shown). Hyperprolactinemia also causes anovulation in women by inhibiting the LH surge (McNeilly, [@B29]). In lactating mice, kisspeptin expression is reduced in both the AVPV and ARC, and lactational anovulation probably results from the selective loss of kisspeptin input to GnRH neurons (Liu et al., [@B24]). Here the decreases in the serum LH, FSH and P4 in TCS mice were corrected by either the quinpirole-corrected increase of PRL or the administration of kisspeptin-10. Kisspeptin replacement can also rescue fertility in hyperprolactinemic rats (Sonigo et al., [@B45]). In mammals, the lactation produces the suppression of GnRH/LH secretion, resulting in transient infertility. In TCS mice, the deficits in follicle development and ovulation could be rescued by L-T4 or the quinpirole-corrected increase of PRL, which was accompanied with regular estrous cycle. Thus, it is conceivable that TCS-induced hyperprolactinemia *via* the suppression of kisspeptin expression may impair the follicle development and ovulation. The level of E2 had no significant difference between control mice and TCS mice. One possible explanation is that the TCS exposure causes the inhibition of estrogen sulfotransferase (EST) to reduce the estradiol metabolism and clearance (James et al., [@B19]).

Based on urinary TCS levels from the National Health and Nutrition Examination Survey (NHANES) survey of 2003 and 2004 (range: 2.4--3, 790 μg/L; Calafat et al., [@B7]), mean daily intake has been estimated as low as 0.2--0.3 μg/kg/day, or up to about 47--73 μg/kg/day based on combined consumer product use (Rodricks et al., [@B42]). The most up to date NHANES survey of 2011--2012 suggests a similar range of urinary TCS levels (1.63--3, 830 μg/L; Witorsch, [@B56]). Wang et al. ([@B54]) recently reported that the levels of urinary TCS are higher in some patients who experienced spontaneous abortion (11.21 μg/L) than those in normal pregnant women (0.99 μg/L). The urinary TCS levels in the pregnant mice treated with 10 mg/kg/day TCS for 5 days is equivalent to those of spontaneous abortion patients with high exposure to TCS. In contrast, the level of urinary TCS (the range of 21.09 ± 5.78 μg/L) in adult female mice exposed to the same dose of TCS for 50 days was increased nearly 2-fold. The plasma concentration of TCS in humans was increased rapidly after a single dose oral administration, attaining peak levels within 1--3 h, resulting in a terminal plasma half-life of 21 h (Sandborgh-Englund et al., [@B44]). However, laboratory experiments under aerobic conditions showed that TCS had a half-life of 18 days (Ying et al., [@B59]). Thus, one possible explanation is that the increase in urinary TCS level of 10-TCS mice may arise from an earlier sampling (12 h urinary after administration of TCS). In addition, further experiments should be done to clarify whether the chronic exposure to TCS affects the degradation rates of TCS leading to the accumulation of TCS. The amount of TCS that entered systemic circulation over the 24 h period is 12% in the feces, 1% in the urine, 30% in the stratum corneum, with 26% remaining on the surface of the skin (Moss et al., [@B30]). Measuring the level of TCS in urine, as an important biomonitoring tool, is used to reflect exposure assessment (Queckenberg et al., [@B40]). The primary elimination route of TCS is through fecal matter and urinary excretion, thus the levels of urinary TCS between 1-TCS mice, 10-TCS mice and 100-TCS mice did not show linear increase. Although the mechanisms underlying TCS-induced suppression of kisspeptin expression remain to be fully elucidated, our data in the present study indicate that exposure to TCS (≥10 mg/kg) in adult female mice through reducing thyroid hormones elevates the level of PRL, which can suppress the neuroendocrine reproductive axis, and ultimately leads to deficits in function of fertility. The findings can help for understanding the influence of TCS exposure in reproductive endocrine and reproductive health in humans.
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